Table of contents
June 2023 - Volume 82 - Suppl 1
EULAR 2023 European Congress of Rheumatology, 31 May - 3 June. Milan, Italy
- Scientific Abstracts
- Oral Presentations
- ABSTRACT OPENING PLENARY
- Epigenetics in chronic inflammation
- Precision medicine in SLE: where are we?
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Comorbidities in RMD
- Improving our understanding of RMDs in children and young people
- From hearts to lungs: comobidities in RA
- GC to new therapies
- Clinical aspects and Treatment of axSpA: effects and predictors of effects
- New clinical aspects in psoriatic arthritis
- Emerging a New Era in Osteoarthritis Therapies
- COVID 19: A pandemic with a long tail
- Fibroblast activation in rheumatic diseases
- Autoinflammation – the next chapter
- Genetics and EpiGenetics of RMDs
- Innate Immunity in Pathogenesis of RMDs
- Pathogenic clues to systemic sclerosis and myositis
- Predictors of outcome in early rheumatoid arthritis
- There is still a lot to SAY about biologicals for RA!
- The future perspectives in the treatment of SLE & Sjören's
- Risk factors and their treatment in the progression of osteoarthritis
- Crystal arthritis: what is new?
- New Insights in the care and management of JIA
- Advances in imaging in rheumatic musculoskeletal disorders
- Single-cell omics in Rheumatic diseases
- Spondyloarthritis across the ages
- Why is performing a good systematic literature review (SLR) so difficult?
- Talking about Remission
- Artificial Intelligence in Medicine: Chances & Challenges
- Clinical and molecular differences across sexes in Rheumatic Disease
- Pain in RMDs
- Understanding Treatment response and novel treatment approaches in RA
- Novel insights into disease taxonomy and immunophenotyping
- Rheumatoid arthritis: new small molecules and old DMARDs
- Updates on management and outcomes in SLE and Sjogren syndrome
- Update on the treatment of scleroderma lung disease
- Osteoporosis
- New evidence on IgG4-related and rare autoinflammatory diseases
- New insights form epidemiology and public health
- Epidemiology, risk and prediction of risk
- The promise of health literacy in clinical care
- Cell activation pathways in RMDs
- Inborn errors of Immunity and autoimmune / inflammatory rheumatic disorders: What can we learn?
- Neutrophil dysregulation in systemic lupus erythematosus
- Insights into gout management
- Exploring the spectrum of bone inflammatory disorders across the life course
- Treating to Target: Challenges across the life course
- Predicting remission and flare
- ANCA-associated vasculitis
- Poster Tours
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Rheumatoid arthritis-aetiology, pathogenesis and animal models
- Contemporary clinical topics in psoriatic arthritis
- RA is more than just joints
- Disease mechanisms in spondylarthritis
- Tapering, drug retention and predictors of response
- All about Crystal arthritis I
- Vessels in flames
- Remarkable Findings in OA Clinical Research
- A novel journey into SLE, Sjogren and APS
- Outcome of scleroderma and related syndromes
- What's new in Paediatric RMDs?
- Pathogenic pathways in Systemic Sclerosis and Myositis
- New developments in imaging in rheumatology
- Systemic lupus erythematosus, Sjogren’s syndrome and anti-phospholipid syndrome: clinical aspects
- bDMARDS in RA 2.0: about the good and the bad
- All about Crystal arthritis II
- People with burning vessels
- Treatment in psoriatic arthritis on the move
- Innate Immunity and Autoinflammation
- Everything you need to know about managing in axSpA
- Pain in RMDs
- All about COVID-19 in Rheumatology
- Advances in our care of children and young people with JIA
- Molecular and metabolic biomarkers of activity, severity and response to treatment
- Clinical aspects of spondyloarthritis
- Original perspectives on old DMARDs and new small molecules in rheumatoid arthritis
- Early RA and comorbidities
- Osteoarthritis: novel prospects
- Beyond the crystal ball
- Genetic Determinants of Clinical Phenotypes
- Impact of sex on disease pathogenesis and outcome
- Health, public health and health services
- Touring the landscape of epidemiology
- Osteoporosis
- Poster View
- Osteo arthritis, aetiology, pathology and animal models
- Spine, mechanical musculoskeletal problems, local soft tissue disorders
- Bone diseases, aetiology, pathology and animal models
- Spondyloarthritis - aetiology, pathogenesis and animal models
- Rheumatoid arthritis - prognosis, predictors and outcome
- Osteoporosis
- Crystal diseases, metabolic bone diseases other than osteoporosis
- Infection-related rheumatic diseases
- COVID-19
- Public health, health services research, and health economics
- Educational cases
- Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models
- Rheumatoid arthritis - biological DMARDs
- Epidemiology, risk factors for disease or disease progression
- Spondyloarthritis - clinical aspects (other than treatment)
- Vasculitis - large vessel vasculitis
- Basic and translational science in paediatric rheumatology
- Paediatric rheumatology
- Clinical cases
- SLE, Sjön’s and APS - aetiology, pathogenesis and animal models
- Rheumatoid arthritis - non biologic treatment and small molecules
- Psoriatic arthritis - clinical aspects (other than treatment)
- Diagnostics and imaging procedures
- Validation of outcome measures and biomarkers
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Innate immunity in rheumatic diseases
- Rheumatoid arthritis - aetiology, pathogenesis and animal models
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rehabilitation
- Education
- Spondyloarthritis - treatment
- SLE, Sjön’s and APS - treatment
- Vasculitis - small vessel vasculitis
- Scleroderma, myositis and related syndromes
- Pain in rheumatic diseases, including fibromyalgia
- Osteoarthritis
- Vasculitis - aetiology, pathogenesis and animal models
- SLE, Sjön’s and APS - clinical aspects (other than treatment)
- Psoriatic arthritis - treatment
- Other orphan diseases
- Publication only
- Genomics, genetic basis of disease and functional genomics
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Innate immunity in rheumatic diseases
- Osteo arthritis, aetiology, pathology and animal models
- Bone diseases, aetiology, pathology and animal models
- Rheumatoid arthritis - aetiology, pathogenesis and animal models
- Spondyloarthritis - aetiology, pathogenesis and animal models
- SLE, Sjön’s and APS - aetiology, pathogenesis and animal models
- Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models
- Vasculitis - aetiology, pathogenesis and animal models
- Basic and translational science in paediatric rheumatology
- Basic and translational pain science
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - biological DMARDs
- Rheumatoid arthritis - non biologic treatment and small molecules
- SLE, Sjön’s and APS - treatment
- SLE, Sjön’s and APS - clinical aspects (other than treatment)
- Vasculitis - large vessel vasculitis
- Vasculitis - small vessel vasculitis
- Scleroderma, myositis and related syndromes
- Spondyloarthritis - treatment
- Spondyloarthritis - clinical aspects (other than treatment)
- Psoriatic arthritis - treatment
- Psoriatic arthritis - clinical aspects (other than treatment)
- Osteoarthritis
- Osteoporosis
- Crystal diseases, metabolic bone diseases other than osteoporosis
- Infection-related rheumatic diseases
- COVID-19
- Pain in rheumatic diseases, including fibromyalgia
- Spine, mechanical musculoskeletal problems, local soft tissue disorders
- Paediatric rheumatology
- Other orphan diseases
- Diagnostics and imaging procedures
- Public health, health services research, and health economics
- Epidemiology, risk factors for disease or disease progression
- Validation of outcome measures and biomarkers
- Rehabilitation
- Education
- NEW TOPIC: Clinical cases
- Clinical cases
- Oral Presentations
- Health Professionals in Rheumatology Abstracts
- Oral Presentations
- Poster Tours
- Poster View
- HPR Epidemiology and public health (including prevention)
- HPR Interventions (educational, physical, social and psychological)
- HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)
- HPR Measuring health (development and measurement properties of PROs, tests, devices)
- HPR Service developments, innovation and economics in healthcare
- HPR Professional education, training and competencies
- HPR Interdisciplinary research
- Publication only
- HPR Measuring health (development and measurement properties of PROs, tests, devices)
- HPR Epidemiology and public health (including prevention)
- HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)
- HPR Professional education, training and competencies
- HPR Interdisciplinary research
- HPR Interventions (educational, physical, social and psychological)
- HPR Service developments, innovation and economics in healthcare
- People with Arthritis and Rheumatism in Europe Abstracts
- Oral Presentations
- "Buy one - get 4 free" - RMDs and comorbidities
- Let’s talk about biomarkers – ask the experts
- 0 – 100 in 75 minutes; RMDs have no age
- E-health - possibilities and pitfalls
- Mind the gap: improving communication and outcomes
- PARE Abstract Session
- Pain relief - what can be done?
- DATA MATTERS: keeping track of your health information
- "So what now?" - living and planning life while co-existing with an RMD
- Poster Tours
- Poster View
- Publication only
- Oral Presentations